Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Development expenses by Year
Development expenses (clinical trials, regulatory & CMC) — Total ($M) ($M)
Vertex Pharmaceuticals Development expenses: $3,082M in FY2025, up 9.1% from a year earlier. That is the highest of the 13 years on record here.
Where the FY2025 figure comes from
“|| Total development expenses | $ 3,081.6 | 9% | $ 2,825.8 | 15% | $ 2,457.3”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K MD&A & Note (Segment Significant Expenses).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up development expenses
- Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M)1,494 · FY2025
- Development — Salary and employee benefits ($M)745 · FY2025
- Development — Stock-based compensation expense ($M)321 · FY2025
- Development — Infrastructure and facilities costs ($M)523 · FY2025
- Development — Outsourced services ex-drug supply (FY2013–FY2018, $M)344 · FY2018
- Development — Clinical drug supply & lab supplies (standalone through FY2018, $M)84.9 · FY2018
Cite this data
StockData. (2026). Vertex Pharmaceuticals Development expenses ($M), annual FY2013–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.